Senior/Executive Medical Director, Clinical Development (New Indications)
Alumis
August 21, 2026
Remote friendly (South San Francisco, CA)
United States
Clinical Research and Development
Position Summary:
Executive Medical Director or Senior Medical Director to lead clinical development strategy and execution for Phase 1 and Phase 2 studies in neurology and additional new indications; scientific leader and external face for the program.
Key Responsibilities:
- Lead design, planning, and execution of Phase 1 and Phase 2 clinical studies for A-005 in neurology (e.g., neurodegenerative diseases, movement disorders) and additional pipeline molecules in inflammatory/immunologic indications.
- Develop/refine clinical development plans (study synopses, protocols, integrated development strategies).
- Provide clinical/scientific leadership to cross-functional teams to ensure alignment on goals, timelines, and deliverables.
- Collaborate with Translational Medicine/Research to evaluate and prioritize new indication opportunities.
- Serve as Medical Monitor for assigned Phase 1/2 studies; ensure patient safety and scientific integrity.
- Oversee medical aspects of study conduct (safety surveillance, protocol amendments, data review).
- Partner with Clinical Operations, Biostatistics, and Regulatory Affairs to ensure efficient execution and high-quality data.
- Lead DSMB interactions and provide medical input for safety analyses.
- Contribute to regulatory strategy; represent the company with FDA and international authorities (EMA/PMDA).
- Prepare/review clinical sections of regulatory submissions (IND amendments, briefing documents, meeting packages).
- Represent company at conferences/advisory boards/KOLs; build relationships with investigators and academic collaborators.
- Integrate biomarker strategies; collaborate on disease landscape/indication prioritization; support BD/in-licensing evaluation.
- Mentor junior medical staff and help build clinical development capabilities.
Required Qualifications:
- MD required; neurology experience required; board certification or fellowship training in Neurology highly desired; inflammatory disease experience (e.g., rheumatology, dermatology) a plus.
- 10+ years in pharma/biotech clinical development with significant neurology focus; immunology/autoimmune experience a plus.
- Demonstrated experience leading Phase 1/2 studies from design through data readout.
- Track record with regulatory interactions (FDA/EMA); experience preparing IND/CTA submissions.
- Deep early-development knowledge (dose-finding, biomarker integration, adaptive designs).
- Strong ability to evaluate preclinical/clinical data; scientific acumen.
- JAK/TYK2 inhibitor or related immunomodulatory mechanism experience preferred.
- Excellent leadership/communication; strategic mindset balancing rigor and business objectives.
Preferred Qualifications:
- Indication expansion/lifecycle management for neurology or immunology assets.
- Experience at a small/mid-sized biotech; comfort in fast-paced, resource-conscious settings.
- Established KOL relationships in neurology (rheumatology/dermatology also valued).
- Experience across multiple indications (neurological and/or inflammatory e.g., psoriasis, psoriatic arthritis, lupus, atopic dermatitis).
- Familiarity with expedited regulatory pathways (Breakthrough Therapy, Fast Track).
Benefits (explicitly stated):
- Competitive compensation with base salary, annual bonus, and equity participation.
- Health, dental, vision, 401(k), and generous PTO; other listed perks include paid insurance premiums (90% employee/80% dependents), $100 monthly cell phone stipend, free Genentech Bus & Ferry access, free onsite gym, and unlimited PTO for exempt employees.
Travel:
- 20–30% travel.
Location/Work schedule (explicitly stated):
- South San Francisco, CA; onsite Tuesday–Thursday; remote case-by-case.
Compensation (explicitly stated):
- $300,000–$400,000 USD annually (estimate; may vary).
Executive Medical Director or Senior Medical Director to lead clinical development strategy and execution for Phase 1 and Phase 2 studies in neurology and additional new indications; scientific leader and external face for the program.
Key Responsibilities:
- Lead design, planning, and execution of Phase 1 and Phase 2 clinical studies for A-005 in neurology (e.g., neurodegenerative diseases, movement disorders) and additional pipeline molecules in inflammatory/immunologic indications.
- Develop/refine clinical development plans (study synopses, protocols, integrated development strategies).
- Provide clinical/scientific leadership to cross-functional teams to ensure alignment on goals, timelines, and deliverables.
- Collaborate with Translational Medicine/Research to evaluate and prioritize new indication opportunities.
- Serve as Medical Monitor for assigned Phase 1/2 studies; ensure patient safety and scientific integrity.
- Oversee medical aspects of study conduct (safety surveillance, protocol amendments, data review).
- Partner with Clinical Operations, Biostatistics, and Regulatory Affairs to ensure efficient execution and high-quality data.
- Lead DSMB interactions and provide medical input for safety analyses.
- Contribute to regulatory strategy; represent the company with FDA and international authorities (EMA/PMDA).
- Prepare/review clinical sections of regulatory submissions (IND amendments, briefing documents, meeting packages).
- Represent company at conferences/advisory boards/KOLs; build relationships with investigators and academic collaborators.
- Integrate biomarker strategies; collaborate on disease landscape/indication prioritization; support BD/in-licensing evaluation.
- Mentor junior medical staff and help build clinical development capabilities.
Required Qualifications:
- MD required; neurology experience required; board certification or fellowship training in Neurology highly desired; inflammatory disease experience (e.g., rheumatology, dermatology) a plus.
- 10+ years in pharma/biotech clinical development with significant neurology focus; immunology/autoimmune experience a plus.
- Demonstrated experience leading Phase 1/2 studies from design through data readout.
- Track record with regulatory interactions (FDA/EMA); experience preparing IND/CTA submissions.
- Deep early-development knowledge (dose-finding, biomarker integration, adaptive designs).
- Strong ability to evaluate preclinical/clinical data; scientific acumen.
- JAK/TYK2 inhibitor or related immunomodulatory mechanism experience preferred.
- Excellent leadership/communication; strategic mindset balancing rigor and business objectives.
Preferred Qualifications:
- Indication expansion/lifecycle management for neurology or immunology assets.
- Experience at a small/mid-sized biotech; comfort in fast-paced, resource-conscious settings.
- Established KOL relationships in neurology (rheumatology/dermatology also valued).
- Experience across multiple indications (neurological and/or inflammatory e.g., psoriasis, psoriatic arthritis, lupus, atopic dermatitis).
- Familiarity with expedited regulatory pathways (Breakthrough Therapy, Fast Track).
Benefits (explicitly stated):
- Competitive compensation with base salary, annual bonus, and equity participation.
- Health, dental, vision, 401(k), and generous PTO; other listed perks include paid insurance premiums (90% employee/80% dependents), $100 monthly cell phone stipend, free Genentech Bus & Ferry access, free onsite gym, and unlimited PTO for exempt employees.
Travel:
- 20–30% travel.
Location/Work schedule (explicitly stated):
- South San Francisco, CA; onsite Tuesday–Thursday; remote case-by-case.
Compensation (explicitly stated):
- $300,000–$400,000 USD annually (estimate; may vary).